[Mar 25, 2026] RAC-US Dumps PDF and Test Engine Exam Questions - ActualPDF
Verified RAC-US exam dumps Q&As with Correct 100 Questions and Answers
The RAC-US certification is a recognized credential that demonstrates that a regulatory affairs professional has the knowledge, skills, and expertise required to navigate the regulatory landscape. Regulatory Affairs Certification (RAC) US certification is offered by the Regulatory Affairs Professionals Society (RAPS), a global organization that represents regulatory professionals worldwide. The RAC-US certification exam is designed to assess the knowledge and skills of regulatory affairs professionals in the United States. RAC-US exam covers various topics such as regulatory strategy, product development, clinical trial design, and post-marketing activities.
The Regulatory Affairs Certification (RAC) US exam is a professional certification program offered by the Regulatory Affairs Professionals Society (RAPS). The RAC-US certification program is designed to validate the knowledge and expertise of regulatory affairs professionals in the United States. RAC-US exam covers a wide range of topics related to regulatory affairs, including FDA regulations, drug development, clinical trials, medical devices, biologics, and healthcare compliance.
NEW QUESTION # 40
Which of the following statements regarding the off-label use of drugs is CORRECT?
- A. The peer-reviewed literature can ensure high-quality off-label promotion of medications, thereby increasing access to much needed drugs and devices.
- B. Sponsors are allowed to distribute publications about unapproved uses of approved drugs and devices as long as the marketing application is under review by the regulatory authority.
- C. Although the regulatory authority reviews and approves drugs for specific indications, the approval does not limit the use of those drugs in clinical practice.
- D. The regulatory authority does not restrict physician prescribing for off-label indications or regulate the manufacturer's promotion for such use.
Answer: C
NEW QUESTION # 41
A regulatory authority announces an inspection of a regulatory affairs professional's facility during a holiday season when most of the staff Is not available. What is the MOST practical approach to this dilemma?
- A. Arrange for an inspection without all intended personnel.
- B. Negotiate with colleagues and the authority to find a better time.
- C. Inform the authority that the time is not suitable and request a new time
- D. Insist that key personnel be available for the inspection.
Answer: B
NEW QUESTION # 42
During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on the part of the PI. What action should the sponsor take?
- A. Increase the frequency of monitoring visits.
- B. Inform the institution that granted a medical license to the Pi.
- C. Terminate the PI and inform the regulatory authorities.
- D. Send a letter of complaint to the Ethics Committee that approved the site.
Answer: C
NEW QUESTION # 43
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy.
The product is marketed in Country X.
where it is regulated as a medical device.
The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y.
The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
- A. Submit the product for review as a pharmaceutical product in Country Y.
- B. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- C. Examine decisions made about similar products in Country Y to propose the classification of the product.
- D. Apply for review of the additional part of the product as a pharmaceutical product in Country
Answer: D
NEW QUESTION # 44
According to ICH, what is the MAXIMUM amount of time in calendar days that an organization has from the initial receipt of information to report serious and unexpected ADR of a marketed product to regulatory authorities?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: D
NEW QUESTION # 45
A company's product was approved by a regulatory authority with the condition that further studies must be completed prior to full approval of the product.
To minimize product-associated risk to patients during the period of conditional approval, what is the LEAST effective way to achieve this goal?
- A. Educate patients and healthcare providers on how to use the product
- B. Promote off-label use to a carefully selected patient population.
- C. Delay product launch until required studies are completed.
- D. Label the product for use in appropriate populations.
Answer: B
NEW QUESTION # 46
GHTF recommends that the medical device manufacturer define the scope of the clinical evaluation based on which of the following?
- A. Essential principles
- B. Risk analysis
- C. Product literature
- D. Instructions for use
Answer: B
NEW QUESTION # 47
According to ICH, how many stability time points are normally required to establish a two- year shelf life for a product?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: A
NEW QUESTION # 48
Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during evaluation by a reimbursement agency?
- A. "Has the product been approved for mor&4nan 10 years?"
- B. "Is the product profitable for the manufacturer?"
- C. "Is the product an established gold standard?"
- D. "Is the product better than currently available alternatives?"
Answer: D
NEW QUESTION # 49
The regulatory authority contacts the regulatory affairs professional regarding a complaint about a drug produced by the company. A consumer reported to the regulatory authority that the tablets have a slightly different color and break easily.
Which of the following actions should the regulatory affairs professional take?
- A. Ask that the regulatory authority provide the actual product subject to the complaint.
- B. Ask that the regulatory authority provide the batch number printed on the packaging of the affected product.
- C. Respond to the regulatory authority that the product subject to the complaint is most likely a counterfeit product.
- D. Respond to the regulatory authority that the company will provide copies of the relevant
QC records for batch release.
Answer: B
NEW QUESTION # 50
Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?
- A. Initiate a global submission process after all submission data are finalized.
- B. Utilize the STED template to complete global requirements.
- C. Identify countries where special requirements exist during the product development phase.
- D. Plan regulatory approval update meetings with senior management and stakeholders.
Answer: C
NEW QUESTION # 51
According to the ICH guideline on GMP for API, to which of the following is the MOST stringent requirement applied?
- A. Isolation and purification
- B. Physical processing and packaging
- C. Introduction of the API starting material
- D. Production of Intermediate(s)
Answer: B
NEW QUESTION # 52
The manufacturer of an API was changed from Company X to Company Y during the late stage of a new drug development. Despite differences in the manufacturing processes of the companies, both APIs meet the current specifications. Which is the MOST appropriate information to include in the final submission documents?
- A. The process information and analytical result of Company X API
- B. The process information and analytical result of Company Y API
- C. Information deemed appropriate by the regulatory authority
- D. The process information and the comparative analytical result of APIs from both companies
Answer: D
NEW QUESTION # 53
A clinical study of a drug is completed to support a marketing approval application.
According to ICH, how long should a sponsor retain the clinical study essential documents?
- A. Three years after the last clinical study site was supplied with investigational drugs
- B. Until the product has been discontinued from marketing in all ICH regions
- C. For a minimum of 10 years after completion of the clinical study
- D. For at least two years after the last approval of an application in an ICH region
Answer: D
NEW QUESTION # 54
A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?
- A. Concept development and early technical design
- B. Early technical design and product release
- C. Concept development and validation
- D. Product release and validation
Answer: A
NEW QUESTION # 55
A company is developing a novel drug to combat AIDS. The preliminary results are very promising and include instances of complete remission. The company has been granted patents in multiple countries for the drug. The regulatory affairs professional is asked to prepare a brief report concerning potential problems for marketing of the product worldwide. Which of the following is the MOST important consideration to discuss?
- A. The time frame in which the patent will expire
- B. Doha Declaration in the TRIPS Agreement
- C. International import and export regulations
- D. The stability of the drug in all zone conditions
Answer: D
NEW QUESTION # 56
A regulation change is imminent and may require further non-clinical testing on a product currently in Phase III clinical trials. What is the most appropriate action to take FIRST?
- A. Obtain a copy of the proposed regulation and analyze the impact.
- B. Consult with the company's legal department regarding options.
- C. Arrange for additional testing of the product at the testing facility.
- D. Inform the company's senior management and arrange an emergency meeting
Answer: A
NEW QUESTION # 57
Why is it necessary to run supplemental safety pharmacology studies?
- A. To evaluate potential adverse pharmacodynamics effects not addressed by the core battery
- B. To substitute the utilization of GLP
- C. To comply with regulatory authority requirements related to clinical studies
- D. To provide adverse reaction reports and the results of the statistical data to the regulatory authority
Answer: A
NEW QUESTION # 58
In addition to protection, what parameters MUST be considered when selecting the primary package (or a product?
- A. Efficacy and material
- B. Volume and material
- C. Compatibility and safety
- D. Safety and efficacy
Answer: C
NEW QUESTION # 59
A company is developing a new line of products in an area that is new to the company.
What is the BEST approach?
- A. Ask the trade association representative to provide an overview of the new product area to the marketing team.
- B. Obtain competitor research and provide the information to the management team.
- C. Obtain regulatory documents and history and provide the information to R&D.
- D. Summarize regulatory documents and history and provide the information to the management team.
Answer: D
NEW QUESTION # 60
During routine surveillance, a regulatory authority sent a company the following communication: "Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product. The regulatory authority is evaluating these issues to determine the need for any regulatory action." Which action would be the most appropriate
FIRST step for the company to take?
- A. Contact the regulatory authority to discuss its findings.
- B. Contact the regulatory authority to argue that its conclusions are wrong.
- C. Repeat the Hepatotoxicity tests and send the results to the regulatory authority.
- D. Wait for the regulatory authority's final publication on its findings.
Answer: A
NEW QUESTION # 61
A company receives multiple complaints regarding the text included on a recently launched product's label. What action should the regulatory affairs professional take FIRST?
- A. Inform the production team.
- B. Notify the regulatory authority.
- C. Recommend an immediate product recall.
- D. Compare the approved text with the product label
Answer: D
NEW QUESTION # 62
......
RAPS RAC-US Test Engine PDF - All Free Dumps: https://www.actualpdf.com/RAC-US_exam-dumps.html
Get New RAC-US Certification – Valid Exam Dumps Questions: https://drive.google.com/open?id=1ILfYtM-JzT8B8dHazIw_jO7ciaBYT9Q1
